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Oxidovanadium complexes with organic ligands are well known to have cytotoxic or differentiating 
capabilities against a range of cancer cell types. their limited use in clinical testing though has 
resulted largely from uncertainties about the long-term toxicities of such complexes, due in part 
to the speciation to vanadate ions in the circulation. We hypothesised that more highly stable 
complexes, delivered using liposomes, may provide improved opportunities for oxidovanadium 
applications against cancer. In this study we sourced specifically hydrophobic forms of oxidovanadium 
complexes with the explicit aim of demonstrating liposomal encapsulation, bioavailability in 
cultured neuroblastoma cells, and effective cytotoxic or differentiating activity. Our data show that 
four ethanol-solubilised complexes with amine bisphenol, aminoalcohol bisphenol or salan ligands 
are equally or more effective than a previously used complex bis(maltolato)oxovanadium(V) in 
neuroblastoma cell lines. Moreover, we show that one of these complexes can be stably incorporated 
into cationic liposomes where it retains very good bioavailability, apparently low speciation and 
enhanced efficacy compared to ethanol delivery. This study provides the first proof-of-concept that 
stable, hydrophobic oxidovanadium complexes retain excellent cellular activity when delivered 
effectively to cancer cells with nanotechnology. This offers the improved prospect of applying 
oxidovanadium-based drugs in vivo with increased stability and reduced off-target toxicity.
There has been interest over many decades in the use of vanadium-derived complexes as pharmacological agents 
to treat human disease, most notably in diabetes and cancer. There are numerous models of such complexes hav-
ing anti-cancer and anti-diabetic effects, both in vitro and in  animals1–5, supporting their potential for therapeutic 
development in humans. However, although metallotherapeutics research with vanadium is long-established, 
there have been limited clinical trials. Such trials indicated that vanadyl sulphate and the oxidovanadium complex 
bis(ethylmaltolato)oxovanadium(IV) (BEOV) could be well tolerated. Nevertheless, the reluctance to pursue 
further trials is based on the potential oxidative and genotoxic effects of high dose vanadium and the fear of 
cumulative, long-term toxicities in off-target  tissues2,6,7. This has certainly generated doubts about applicabil-
ity for chronic diseases such as  diabetes8,9. However, these issues may be of lesser concern for cancer patients 
undergoing short-term treatments. This has encouraged continued investigation of improved vanadium deriva-
tives with anti-cancer  potential10–12. In addition, more recent technologies make it increasingly possible to target 
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drug molecules more precisely to tumour tissues, ameliorating off-target problems. This may allow vanadium 
complexes to remain as a potential therapeutic platform.
Vanadium exists in oxidation states − III to + V, but in biological solutions the majority is in the form of vana-
dyl cations (IV) or vanadate ions (V)13. Orthovanadate has a tetra-coordinated structure with the vanadate ion at 
the centre, similar to a phosphate group. Because of this, vanadate is a broad specificity and reversible inhibitor 
of protein tyrosine phosphatase (PTP)  enzymes5,14,15. This is considered one of its major biochemical effector 
mechanisms and PTPs are key players in many signalling pathways that contribute to the onset and progression 
of  cancer16–18. Nevertheless, the similarity to phosphate means that vanadate can accumulate in tissues with 
high phosphate content, such as  bone3,4,19,20. One approach for tackling this issue has been the development of 
oxidovanadium complexes with a wide range of organic ligands. These include maltolato vanadium complexes, 
vanadocenes, and peroxidovanadium  complexes3. Such complexes do not mimic phosphate and are commonly 
too large to act as PTP inhibitors themselves, but they have improved oral bioavailability in vivo compared to 
vanadate, effectively permitting better vanadium absorption by the gut and release into the  circulation4,21. In 
some cases, the oxidovanadium complexes are also made with the intention of delivering toxic ligands. However, 
all of these complexes are subject to rapid ligand exchange and speciation in the gut or circulation, releasing or 
rearranging the ligands and generating vanadium complexation with proteins such as albumin or transferrin, 
or with citrate and ascorbate, before reaching target  cells9,10,22–28. This common instability of oxidovanadium 
complexes and release of circulating vanadate is considered a potential hindrance to their clinical application. 
Therefore, to harness better the anti-cancer properties of vanadium, it would be advantageous to consider care-
fully the choice of more stable complexes, and how they could be delivered to cells with minimal speciation.
We have hypothesised that highly hydrophobic oxidovanadium complexes may offer better stability in 
aqueous environments. This is supported by studies of Reytman and co-workers who showed that diamino 
tris(phenolato) liganded vanadium ions can generate hydrophobic and stable complexes with good anti-cancer 
activity in HT-29 colon carcinoma  cells29. We further hypothesised that hydrophobicity would offer an alternative 
delivery route for such complexes using nanotechnology. Nanocomposite carriers containing metavanadate and 
chitosan have been used in mouse models of type 2  diabetes30,31, while polyethylene glycol (PEG) lipid micelles 
containing vanadium disulphide nanodots displayed tumour uptake in mice for image-guided photo thermal 
cancer  therapy30–32. Although at the time of our study there were no examples of nanotechnology being used 
to deliver larger oxidovanadium complexes, we considered that liposomes would offer a good delivery vehicle 
due to the hydrophobicity of the complexes. Liposomes have already been proven to successfully deliver both 
hydrophilic and hydrophobic molecules to cancer  cells33,34 and liposomes could also provide protection against 
oxidovanadium complex speciation in the bloodstream as well as targeting possibilities in solid tumours. Once 
delivered into cells in this manner, we would nevertheless still expect intracellular speciation to occur.
Our previous studies demonstrated that the complex bis(maltolato)oxovanadium(IV) (BMOV) is both cyto-
toxic and differentiative in neuroblastoma tumour-derived cell  lines35,36. Since BMOV is water soluble and not 
particularly stable in aqueous environments, our aim was to identify alternative, hydrophobic oxidovanadium 
complexes and to demonstrate for the first time their cytotoxicity in neuroblastoma tumour cells when deliv-
ered with liposomes. Here we demonstrate this approach using a class of highly hydrophobic V(V) complexes 
with aminoalcohol bisphenol and salan ligands that we have described  previously37–39. Our data confirm the 
cytotoxicity and differentiating capacity of each compound in several neuroblastoma cell lines and, moreover, 
we successfully deliver one of these complexes to cultured neuroblastoma tumour cells using liposomes, where 
it retains good bioavailability and efficacy.
Results
Cytotoxicity of hydrophobic oxidovanadium complexes compared to BMOV. Oxidovana-
dium complexes with organic ligands are effective anti-cancer agents in experimental models, including 
 neuroblastoma2,3,5. Most of these complexes are water soluble, such as BMOV, and in aqueous environments 
such as culture media or serum can be subject to dissolution into their component parts of vanadate and soluble 
 ligands10,22–25. Our first aim was to identify complexes that are water insoluble and retain similar properties to 
BMOV in being effective as cytotoxic and differentiative agents in neuroblastoma cells. Such complexes would 
then be evaluated for liposomal delivery.
We have previously prepared a series of amine bisphenol oxidovanadium complexes (AL2–AL4 in Fig. 1), 
which are highly insoluble in aqueous  solutions37–39. A salan complex AL1 is also highly insoluble in  water38. 
While analogous to iso-propanolate derivative  L7VO(OiPr), which had previously been shown to have little cyto-
toxicity in OVCAR01 or HT29 tumour  cells40, we wished to assess AL1 in neuroblastoma cells. The aminoalcohol 
bisphenolate complexes, AL2 and AL3 or amine bisphenolate complex AL4 have not been tested on cells before.
The compounds were very poorly soluble in DMSO and so we assessed the cytotoxic potential of AL1–4 
against neuroblastoma-derived tumour cell lines when delivered in sub-toxic levels of ethanol. Cytotoxicity was 
then compared to  BMOV35,36. Maximal solubilities in ethanol ranged from 500 µM (AL3) to 10 mM (AL1,2,4), 
producing distinctly coloured solutions that were very stable at room temperature. Neuroblastoma cells were 
treated with 5 µM or 10 µM of AL1, AL2 and AL4 for 3 days. Due to its particularly poor solubility, AL3 was 
used at 2.5 µM and 5 µM. Treated IMR32 and KELLY cells showed clear evidence of cytotoxicity, with initially a 
poorly adhesive morphology preceding the appearance of apoptotic or necrotic cell bodies, similar to that seen 
previously with  BMOV35. The morphological cytotoxicity of the oxidovanadium complexes was lower in KELLY 
than in IMR32, with poorly-adherent KELLY cells surviving better and possibly increasing cell numbers at low 
chemical doses (Supplementary Fig. S1). All of the hydrophobic oxidovanadium complexes appeared equally 
or more effective as equivalent doses of BMOV. The 5 µM AL3-treated cells experienced qualitatively greater 
cytotoxicity compared with the other complexes at 5 µM, more similar to their 10 µM doses. Surviving cells were 
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then quantified using Hoechst for nuclear counting. This Hoechst method was more accurate than MTS-based 
metabolic assays, since oxidovanadium complexes interfered with the MTS metabolic readout (data not shown). 
The data reveal again that all complexes except AL3 had similar potency as BMOV (Fig. 1B,C). We again noted 
the growth stimulation at low doses, but the basis for this biphasic response remains unclear. When comparing 
 EC50 values, AL3 is at least 2.4-fold more potent than other complexes in KELLY cells, and at least 3.7-fold more 
potent in IMR32 cells (Table 1; Supplementary Fig. S2). We conclude that these four complexes can be delivered 
in ethanol-solubilised forms to cultured neuroblastoma cells, where they evidence similar, or in the case of AL3 
significantly greater, cytotoxicity compared to BMOV.
Glutathione suppression enhances cytotoxicity. Our previous work shows that glutathione (GSH) 
suppression by buthionine sulfoximine (BSO) enhances BMOV-induced cytotoxicity in neuroblastoma cells, 
possibly by shifting vanadium to its most oxidised  state35. This previous study demonstrated that several neu-
Figure 1.  Structures and cytotoxicity of oxidovanadium complexes. (A) Structures of oxidovanadium 
complexes. AL1 has a diamine bis (phenolato) tetradentate ligand (a salan), AL2–4 have aminoalcohol 
bisphenol ligands, and all have coordinated V(IV) ions. AL1–4 are highly water insoluble. BMOV has maltolato 
ligands, a coordinated vanadium(V) ion and is water soluble. (B,C) cytotoxicity of oxidovanadium complexes 
in IMR32 and KELLY cells. IMR32 (B) and KELLY (C) cells were treated with increasing concentrations of 
oxidovanadium complexes up to 10 µM for BMOV and AL1,2,4 and up to 5 µM for AL3. After 3 days, cells were 
stained with Hoechst and nuclei were counted and normalised to ethanol-only treated cells (n = 3, SD shown).
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roblastoma cell lines, including IMR32, tolerate up to 200 µM BSO with little deleterious effect. Here we show 
that 10 µM BSO suppresses GSH by 65% (IMR32) and 75% (KELLY) (Fig. 2G), yet again BSO has no significant 
effect on cell survival when used alone (Supplementary Fig. S3). To assess whether BSO enhanced the cytotoxic-
ity of AL1–4, KELLY cells were treated with both AL1–4 and BSO (Fig. 2A–E). The BSO doubled the cytotoxicity 
of 5 µM AL1, AL2 and AL4, to a related degree as seen with BMOV (Fig. 1F). With AL3 the cell survival was 
already low and BSO suppressed this further but not to statistical significance. The AL1–4 complexes therefore 
show enhanced cytotoxicity during glutathione suppression, confirming that they behave in a similar manner 
to  BMOV35. 
Glutathione depletion does not correlate with AL1–4 cytotoxicity. One property of oxidovana-
dium complexes is their potential to generate reactive oxygen species (ROS), which in turn can induce non-
specific  toxicity13,41. We have shown previously that BMOV appears not to kill cells using this  mechanism35. Total 
cytoplasmic glutathione levels, as the cell’s major antioxidant defence, can be used as an approximate reflection 
of oxidative stress, since oxidised glutathione is exported from cells. Total intracellular glutathione was meas-
ured using monochlorobimane (MCB) following 24 h of oxidovanadium compound  treatment42. As expected, 
glutathione was significantly reduced by BSO in IMR32 and KELLY, but there was no significant change in glu-
tathione after treatment with either BMOV or AL1–4 (Fig. 2G). These data suggest that elevated ROS production 
is unlikely to be a major factor underlying the cytotoxicity of these complexes.
Induction of cell differentiation. Oxidovanadium complexes such as BMOV can elicit the positive 
response of neuronal differentiation in some neuroblastoma cell lines such as SK-N-SH36. SK-N-SH were there-
fore treated for 5 days with BMOV and AL1–4, and neurite lengths were measured as a parameter of differentia-
tion (Fig. 3). All complexes induced differentiation. Although the data scatter precluded statistical significance, 
the complexes were all more effective on average than BMOV, with AL3 generating the longest neurites. These 
hydrophobic oxidovanadium complexes can all therefore trigger morphological, neural differentiation in SK-N-
SH cells, rather than cytotoxicity, in a similar manner to BMOV.
AKT and ERK activation by AL1–4. Increased phosphorylation of AKT and ERK is characteristic of 
neuroblastoma cells treated with BMOV and  vanadate35,36. To assess whether AL1–4 similarly enhance these 
signalling events, IMR32, KELLY and SK-N-SH cells were treated with 10 µM BMOV, AL1, AL2 and AL4, and 
5 µM AL3. In IMR32 cells the phosphorylation of AKT was weakest with BMOV, AL3 and AL4, but stronger 
with AL1 and AL2. In IMR32, phosphorylation of ERK was not significantly enhanced by BMOV, AL2 and AL4, 
but was enhanced most by AL1 and AL3 (Fig. 4A–C). In KELLY cells, phosphorylation of both AKT and ERK 
is enhanced strongly and similarly by BMOV, AL2 and AL4, but even more strongly by AL1. In contrast, AL3 
only weakly stimulated ERK and AKT phosphorylation (Fig. 4A–C). In SK-N-SH cells, phosphorylation of AKT 
was strongly enhanced by BMOV and more strongly again by AL1,2,4 (Fig. 4D–F). AL3 was the weakest of the 
AL complexes in stimulating pAKT. In SK-N-SH, pERK was generated similarly by all complexes, but quanti-
tation showed that on average AL2 was weakest and AL1 strongest. AL1–4 can therefore stimulate pAKT and 
pERK similarly to, and sometimes more than, BMOV, with compound AL1 stimulating the greatest biochemi-
cal changes in all three cell types. Although some of AL3’s reduced signaling in KELLY and SK-N-SH could be 
explained by the lower dose of 5 µM used, the further qualitative differences seen, for example high stimulation 
of pERK in IMR32, suggest that AL3 has distinct effector properties. The data also indicate that stimulation of 
AKT and ERK signaling do not correlate with the relative cytotoxic potential of AL1–4 (Fig. 1). This potentially 
concurs with our previous conclusions that BMOV does not require AKT or ERK activation for its  cytotoxicity35.
In summary, the above data show that AL1–4 have broadly similar cellular and biochemical properties 
compared with BMOV in KELLY, IMR32 and SK-N-SH, while generating more potent effects in some cases.
AL1–4-induced responses are not driven by their organic ligands. Oxidovanadium complexes 
with diverse liganding molecules have been used in many cancer  models43,44. The ligands in some cases have 
intrinsic anti-cancer properties and the dissociation or speciation of complexes in the gut or circulation is viewed 
as a pharmacological problem due to off-target  toxicities9,10,22,23,45–47. In this project we aimed to use the ligands 
to facilitate oxidovanadium delivery, rather than acting toxically themselves. Since AL1–4 have some quantita-
tive differences in cellular potency and qualitative differences in biochemical responses, they are unlikely to be 
Table 1.  Mean  EC50 calculations from cell survival curves generated for Fig. 1B,C (n = 3). Cells were treated 
for 3 days with oxidovanadium complexes before assaying cell numbers. a Estimated values only for KELLY, 
generated through extrapolation of Fig. 1C curves to reach the 50% survival point.
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simply releasing common, dissociated vanadate before entering the cell. It is feasible instead that the ligands 
may be generating some of these differences. The ligands themselves were therefore investigated for cytotoxic 
and cell signaling potential (Fig. 5). Free ligands were dissolved in ethanol and cells were treated for 3 days. 
Figure 2.  The relationship of glutathione dynamics to cytotoxicity and ROS production. (A–E) BSO treatment 
enhances oxidovanadium complex-induced cytotoxicity in neuroblastoma cells. KELLY cells were treated with 
increasing concentrations of oxidovanadium complexes (up to 10 µM for BMOV and AL1,2,4, and 5 µM for 
AL3) with and without 10 µM BSO for 3 days, after which surviving cells were quantified using nuclei staining 
and normalised to ethanol-only values (n = 3). (F) surviving cell numbers in KELLY cells treated with ethanol 
(etoh) or 5 µM oxidovanadium complexes with and without 10 µM BSO, with statistical analysis carried out 
with ANOVA and Bonferroni post hoc, ns not significant, ***p < 0.001 (n = 3). (G) effect of oxidovanadium 
complexes on cellular glutathione levels. IMR32 and KELLY cells were untreated (UT) or treated with BSO, 
BMOV and AL1–4 at the concentrations shown. After 24 h, the relative, reduced glutathione levels were assessed 
using MCB. ANOVA with Dunnett post hoc for each cell line using UT. ***p < 0.001 (n = 3).
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These free ligands had no observable cytotoxic effects on IMR32 cells (Fig.  5B). SK-N-SH cells treated with 
AL1–4 generated extended neurites, whereas treatment with the ligands did not (Fig. 5C). Western blotting of 
SK-N-SH lysates showed that while AL1–4 stimulated phosphorylation of AKT and ERK, the ligands again did 
not (Fig. 5D–F). These data thus demonstrate that the ligands in AL1–4 do not have cytotoxic, differentiative or 
AKT/ERK signaling properties in these tumour cells. We have also demonstrated that molybdenum complexes 
with the same ligand as AL2 are not cytotoxic in IMR32 and do not induce differentiation in SK-N-SH cells 
(Supplementary Fig. S4).
Liposomal delivery of AL3. The hydrophobic complexes AL1–4 display similar or stronger activ-
ity than BMOV in neuroblastoma cells and may, therefore, have potentially improved anti-cancer activ-
ity. However, their strong hydrophobicity would present delivery and bioavailability barriers in  vivo. Our 
second, key aim therefore was to demonstrate that these complexes can be delivered using a method that 
should in future be compatible with systemic delivery and stability. The approach we have initially tested is 
that of liposomal encapsulation of AL3, followed by tests of its bioavailability in cultured neuroblastoma 
Figure 3.  Hydrophobic oxidovanadium complexes induce neurite outgrowth. (A) SK-N-SH cells were treated 
with 5 µM oxidovanadium complexes for 5 days, scale bars = 100 µm. Neurites are indicated with white arrows. 
(B) relative neurite length measurements after 5 days. **p < 0.01 (n = 3) compared to ethanol (ETOH).
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tumour cells. AL3 was chosen for this liposomal testing since it was the most hydrophobic and demonstrated the 
greatest cytotoxicity and differentiative potential.
AL3 was incorporated into liposomes derived from DOPC, a neutral lipid used to promote stable lamellar 
structures, cholesterol to increase stability of the liposomes, and DOTMA as a cationic lipid to improve uptake 
in mammalian  cells48. Liposomes containing AL3 were cationic with an average charge of 64 ± 3 mV, a mean 
diameter of 159 ± 16 nm and polydispersity index of 0.33 ± 0.04. A reverse-phase HPLC assay was used to measure 
the concentration of AL3 incorporated into three liposome  batches49 (Fig. 6A,B). A mean of 131 µM across three 
liposome batches was calculated, albeit with a broad range, compared with the theoretical maximum loading of 
154 µM (Fig. 6F). This showed that, on average, up to 85% of AL3 was incorporated into the lipid compartment 
of the liposomes. To separate encapsulated from non-encapsulated AL3, liposomes were dialysed within 48 h of 
synthesis, using dialysis chambers with a molecular weight cut-off of 10 KDa. Size and charge analysis showed 
no significant changes after dialysis, and AL3 quantitation showed only a small and not statistically significant 
decrease of AL3 concentration after dialysis (Fig. 6F). This indicates that AL3 can remain stably incorporated in 
Figure 4.  Induction of AKT and ERK signalling by hydrophobic oxidovanadium complexes. (A) IMR32 and 
KELLY cells were treated with 10 µM BMOV and AL1,2,4, and 5 µM AL3 for 48 h. Representative immunoblots 
for phosphorylated and total AKT and ERK are shown; the AKT bands are taken from different exposures of 
the same gel. (B,C) Immunoblots were quantified and relative band intensities for phosphorylated proteins 
were normalised to total AKT or ERK proteins (n = 3). (D) SK-N-SH cells were treated with 10 µM BMOV and 
AL1,2,4 and 5 µM AL3 for 72 h. Representative immunoblot detecting phosphorylated and total AKT and ERK 
is shown. (E,F) immunoblots were quantified and relative band intensities for phosphorylated proteins were 
normalised to total AKT or ERK proteins. ANOVA with Dunnett post hoc for each cell line using untreated 
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these liposomes for at least 48 h (Fig. 6C,D). In the experiments below, we used the theoretical concentrations 
of AL3 based on maximal loading, rather than the actual amount loaded. This was necessary since we needed 
to maintain consistency in, and also to minimise, the quantity of liposomal material we treated the cells with.
Cytotoxic activity of liposomal AL3. To assess the cellular bioavailability and activity of liposomal AL3, 
IMR32 cells were treated with liposomes for 6 days at 0.25 µM AL3. Higher concentrations of AL3 could not be 
used in IMR32 because they become subject to non-specific toxicity from these particular liposomes. Neverthe-
less, at 0.25 µM the liposomal AL3 generated a 25–30% reduction in cell viability over 6 days (Fig. 7A). This 
equates approximately to the toxicity seen with the equivalent of 0.8 µM of ethanol-solubilised AL3 over 3 days 
(Fig. 1B). Although these treatments are for different times, the cells appear to be responding similarly given that 
the 0.25 µM of ethanol-solubilised AL3 in Fig. 7A causes a small increase in cell numbers that remains compa-
rable to that seen in Fig. 1B.
Cell differentiation by liposomal AL3. To measure the stimulation of cell differentiation, the neuronal 
SK-N-SH cells were treated with BMOV or AL3 in solution, with dialysed and non-dialysed liposomal AL3, 
or with empty liposomes. Average neurite lengths were quantified after 5 days (Fig. 7B). BMOV and ethanol-
solubilised AL3 induced increased neurite outgrowth. Neither the empty liposomes, nor BMOV or AL3 in solu-
tion at concentrations below 5  µM affected neurite length in SK-N-SH, and they were not toxic. Liposomal 
AL3, dialysed and non-dialysed, was better tolerated in SK-N-SH than seen with IMR32 above and significantly 
increased neurite length at 0.5 µM and 1 µM AL3 (Fig. 7C). Similar neurite outgrowth stimulation was obtained 
with a second liposomal AL3 batch. A third batch (batch3; Fig. 6E) stimulated lesser neurite outgrowth, but 
had lower undialysed AL3 content (Fig. 7D). At 1 µM, undialysed and dialysed liposomal AL3 increased neu-
rite lengths to a greater or equal extent, respectively, to those seen with 5 µM soluble AL3 (Fig. 7C). There is a 
small, but not significant, decrease in neurite length relating to dialysis, broadly mirroring the difference in AL3 
concentration in these formulations as described Fig. 6E. These data therefore indicate that liposomal AL3 has a 
fivefold greater differentiation capacity than AL3 delivered in ethanol.
Biochemical signaling by liposomal AL3. To test whether liposomal AL3 can trigger AKT signalling, 
SK-N-SH cells were treated for 3 days with BMOV or AL3 in solution, and with dialysed and non-dialysed AL3 
liposomes (Fig. 8). Since SK-N-SH could tolerate higher levels of liposome treatment than IMR32, we used up 
to 1 µM liposomal AL3 and comparable empty liposome quantities. Significant increases in phosphorylation of 
AKT were observed in cells treated with 1 µM liposomal AL3, both in dialysed and non-dialysed forms. Similar 
to the differentiation data, liposomal AL3 was more effective at stimulating signaling compared to ethanol-
Figure 5.  Cellular and biochemical effects of ligands. (A) Ligands 1–4 are from the respective hydrophobic 
oxidovanadium complexes AL1–4. (B) IMR32 cells were treated with 10 µM oxidovanadium or ligands only 
(5 µM for AL3 and L3) for 3 days. Relative cell numbers were assessed using nuclear counting. ANOVA with 
Dunnet post hoc using untreated (UT) as control, ***p < 0.001 (n = 3). (C) SK-N-SH cells were treated with 
either 5 µM oxidovanadium complexes or respective ligands for 6 days, after which relative neurite lengths were 
assessed. ANOVA with Dunnet post hoc using UT as the control, *p < 0.05, **p < 0.01 (n = 3). (D) representative 
immunoblot for phosphorylated and total AKT and ERK performed using protein lysates from SK-N-SH cells 
in (C). (E,F) Immunoblots were quantified from 3 independent experiments and relative band intensities for 
phosphorylated proteins were normalised to total AKT or ERK. ANOVA with Dunnett post hoc was applied 
using UT as the control, **p < 0.01, ***p < 0.001. Original gels are shown in Supplementary Fig. S7.
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solubilised AL3. These data indicate that AL3 can be successfully packaged into liposomes and that liposomal 
delivery improves the ability of AL3 to counter the cancer cell phenotype compared with ethanol-solubilised 
AL3 in cultured neuroblastoma cells.
Discussion
The four oxidovanadium complexes described in this study are based on amine bisphenol, aminoalcohol bisphe-
nol or salan ligands. They are highly hydrophobic and are able to effect either cytotoxicity or differentiation in 
several neuroblastoma tumour-derived cell lines. They are also as effective, or more effective, than the previously 
documented actions of a water soluble oxidovanadium complex BMOV in these  cells35,36. The current study is 
also significant in that it demonstrates for the first time that with liposomal technology such oxidovanadium 
complexes can be made bioavailable and show increased anti-neuroblastoma cell activity.
The oxidovanadium complexes AL1–4 behave similarly to BMOV in that their effects are enhanced by block-
ade of GSH production. This may relate to the fact that tumour cells, including MYCN-amplified neuroblas-
toma cells, harbour elevated levels of GSH to compensate for, and defend against, higher ROS  production50. A 
minority of neuroblastoma tumour cell lines are also directly sensitive to GSH depletion  itself51. Oxidovana-
dium is sensitive to the REDOX state of cells and our complexes become more toxic when GSH is depleted. As 
previously hypothesised with  BMOV35, the more oxidising conditions should generate higher cellular levels of 
the vanadium(V) ion, which is a more effective phosphatase  inhibitor35, and consequently higher cytotoxicity. 
Oxidovanadium complexes can have lower cytotoxicity in non-tumour cells compared to tumour  cells35,52,53 and 
it will be of interest to examine if this relates to these cells’ more reducing environment.
It is also of interest that low doses of these complexes increase cell numbers in KELLY, and to a lesser 
degree in IMR32, before switching to cytotoxicity at higher doses. This has been described before in MC3T3E1 
osteoblast-like  cells54 but is still not understood. It may relate to the differential sensitivity of the multiple PTP 
targets of oxidovanadium. Additionally, oxidovanadium has diverse biochemical effects in cells and this may be 
concentration-dependent and also differentially controlled by cellular REDOX state. Nevertheless, when used 
in vivo, oxidovanadium compounds including BMOV are reasonably well tolerated while having chemopreven-
tive and anti-tumour  activities2. This indicates that a therapeutic window may be possible with such compounds.
These four oxidovanadium complexes have distinct organic ligands and their relative potencies were quanti-
tatively and qualitatively distinct. AL3 induced strong phosphorylation of ERK in IMR32 but not KELLY cells, 
Figure 6.  Oxidovanadium complex loading into liposomes. Three batches of AL3 liposomes were synthesised 
then dialysed over 24 h against water. Reverse-phase HPLC was used to measure AL3 concentration; example 
UV absorbance traces for ethanol solubilised (A) and liposomal (B) AL3 are shown. AL3 concentration was 
assessed using absorbance at 360 nm (black arrows). Average liposome charge (C), size (D) and polydispersity 
(E) were measured before and after dialysis (n = 3). (F) Liposomal AL3 concentration was calculated pre- and 
post-dialysis in three batches of liposomes.
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despite AL3 being used at a lower dose than the other complexes, while both cell lines have a strong cytotoxic 
response to this compound. AL1 drove the strongest phosphorylation of AKT and ERK, but was less toxic than 
AL3 and no more cytotoxic than AL2 or AL4. Although we have shown previously that ERK and AKT activation 
by BMOV are not needed for its  cytotoxicity35, this qualitative uncoupling of the morphological and biochemical 
responses to AL1–4 was not foreseen and may again indicate the lack of necessity for ERK or AKT activation for 
neuroblastoma cell death or differentiation.
In seeking to understand the basis for the differences in their actions, it was shown that the complexes 
appeared not to differ significantly in terms of glutathione depletion, and there were no correlations between 
glutathione levels and cytotoxic capacity. Thus, ROS production through interconversion between the vanadyl 
(IV) and vanadate (V) redox  states13 may not be a significant cytotoxic factor here. The qualitative distinctions 
between AL1–4 also suggest that these complexes are not simply speciating outside cells and acting as vehicles 
for common, bioactive vanadate. Since AL1–4 have distinct ligands, it is possible that the ligands are generating 
the complexes’ quantitative and qualitative differences. In less stable oxidovanadium complexes, speciation can 
release ligands that are themselves  toxic23,24,45. However, our data indicate that free ligands from AL1–4 have 
no recognisable biological activity. It is possible that the ligands alone do not enter cells efficiently, but can be 
carried in by the intact complexes, where they then dissociate and have access to novel targets. This is unlikely 
in our view, but cannot be excluded currently.
Why is AL3 the most cytotoxic in KELLY and IMR32 cells and is the strongest differentiating agent in SK-N-
SH? Although the complex may simply enter cells more efficiently than the others, its unique AKT/ERK signalling 
pattern would not be consistent with this scenario. It will be of interest in future to examine the relative efficacies 
of the other compounds when delivered in liposomes, as liposomes may provide more uniform cellular delivery. 
Figure 7.  Biological effects of AL3-containing liposomes in neuroblastoma cells. (A) IMR32 cells were treated 
for 6 days with BMOV or AL3 in solution, empty liposomes, or AL3 liposomes (batch 1; both undialysed and 
dialysed [D]) after which cell viability was assessed by nuclei counting. ANOVA with Dunnet post hoc using 
ethanol (etoh) as the control, *p = 0.053 (n = 3). (B) SK-N-SH cells were treated for 5 days with BMOV or AL3 
in solution, undialysed empty liposomes, or batch-1 undialysed (AL3 LIPO) and dialysed (AL3 LIPO DIA) AL3 
liposomes. Neurite formation (white arrows) is indicated. (C) Neurite lengths were measured after treatments 
with BMOV, AL3, empty liposomes and AL3 liposomes. Dialysed liposome treatments are indicated as “dia”. 
Empty liposome dosage in parenthesis matches the lipid content of those used in the equivalent AL3 liposome 
treatments. ANOVA with Dunnett post hoc using untreated ethanol (etoh) as control **p < 0.01, ***p < 0.001 
(n = 3). (D) SK-N-SH cells were treated in the same way as in (B) and (C), using batch 2 and 3 AL3 liposomes, 
showing batch 1 data again for comparison. Mean average effects on neurite length are shown.
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AL3’s higher activity might instead be explained by it having access to specific, intracellular compartments, pro-
viding selective access to differentially localised  PTPs55–57. For example, a distinct oxidovanadium compound, 
decavanadate, has been reported to induce mitochondrial membrane depolarisation by localising selectively to 
 mitochondria58. Furthermore, although it is likely that AL1–4 speciate inside cells, releasing vanadate, they may 
also have some differential abilities to inhibit PTPs as intact complexes. For example, the cis-aquo form of BMOV 
can fit favourably inside the active site of PTP-1B, at least through structural  modelling59. However, AL1–4 have 
additional, bulky tert-butyl groups on their phenolic rings and these are likely to preclude access to the PTP active 
sites. Intact AL1–4 could even have other non-PTP targets in cells and further studies are therefore required in 
order to explain the cellular and biochemical responses to AL1–4.
An iso-propoxide analogue of AL1,  L1VO(OiPr), with the same tert-butyl-substituted salan ligand, has been 
described as being non-cytotoxic in HT29 colorectal and OVCAR-1 ovarian cancer  cells40. It was suggested, but 
not demonstrated, that this was due to either its stronger hydrophobicity, poor membrane accessibility or inability 
to associate with intracellular  targets40. In contrast, AL1 is evidently cytotoxic in neuroblastoma cells and can 
also induce neuronal differentiation. We currently do not know why it shows this activity in neuroblastoma cells 
compared to HT29, but the somewhat less hydrolytically stable methoxide versus more stable iso-propoxide 
modification, may contribute. The team that generated  L7VO(OiPr) later developed hydrophobic and highly 
stable diamino tris(phenolato) liganded oxidovanadium complexes and showed their high cytotoxicity in cul-
ture and ability to suppresses HT-29 tumours in vivo29. Our data with complexes AL2–4 therefore concur with 
Reytman’s study, supporting the improved therapeutic opportunities that could be offered through use of such 
stable, hydrophobic oxidovanadium complexes.
Although hydrophobic complexes AL1–4 may offer improved anti-cancer opportunities, such complexes 
would present challenges as therapeutics due to their extreme insolubility. Our key aim here was to bring nano-
technology to bear on this problem and demonstrate cellular delivery of the complexes using liposomes. In this 
study we used cationic liposomes, having previously found that related cationic formulations are effective in 
drug delivery in culture and in vivo and are poor activators of the complement  system60,61. Our previous work 
on RAMBA chemicals that are similarly hydrophobic to the present oxidovanadium complexes, also showed 
very effective payload delivery by liposomes in under 24 h, and others describe this occurring in under 6 h48,62,63. 
We demonstrated here in this proof-of-principle study that the liposomal delivery approach for oxidovana-
dium complexes works well under cell culture conditions. This is as far as we know the first demonstration of 
liposomal-dependent bioavailability of hydrophobic oxidovanadium complexes, with apparent enhancement of 
Figure 8.  Enhancement of AKT phosphorylation by liposomal AL3. (A) SK-N-SH cells were treated with 
BMOV or AL3 in solution, empty liposomes, or batch-1 AL3 liposomes (both dialysed and dialysed) for 3 days. 
An example immunoblot is shown showing pAKT stimulation levels; this is quantified in (B) along with two 
further datasets (n = 3). ANOVA was performed with Dunnett post hoc using untreated (UT) as the control, 
*p < 0.05, ***p < 0.001. (C) SK-N-SH were treated in the same way using batch 2 and 3 of the AL3 liposomes and 
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cytotoxic and differentiative potential. Interestingly, as we completed this work, a biophysical study documented 
the successful loading of liposomes with a curcumin complex of oxidovanadium. It will be interesting to see in 
future whether these are also effective at delivering curcumin to cancer  cells64.
Liposomal formulations are used for delivery of a range of anti-cancer drugs in human trials and some 
are now in the  clinic65. This has also been recently reviewed for  neuroblastoma66. Liposomes can penetrate some 
solid tumours by ‘passive targeting’ through the enhanced permeability and retention (EPR)  effect67. Although 
this appears feasible in neuroblastoma xenograft  models68,69, it is unclear whether EPR is relevant here clinically. 
The delivery of oxidovanadium complexes in vivo for neuroblastoma would likely need more advanced liposomal 
technology, such as tumour targeting with RGD-based  peptides60,69, or antibodies specific for disialoganglioside 
2 (GD2), a key antigen on neuroblastoma  cells70,71. PEGylated lipids can also be employed. PEGylation often 
reduces transfection efficiency in cultured  cells72,73, whereas in vivo they increase liposomal longevity in the 
bloodstream and reduce immunological responses and drug  toxicities73–75.
The potential benefits of a liposome-based route of oxidovanadium complex delivery are several-fold. First, 
the hydrophobic complexes would likely partition strongly in the liposomes rather than the aqueous circula-
tion, discouraging speciation and encouraging stability. We would in future nevertheless need to examine this 
liposomal stability under high serum conditions in vivo, even though we have shown that similar liposomal 
systems can deliver payloads quite efficiently either systemically or  locally61. Second, if the more targeted and 
selective delivery of oxidovanadium to tumour tissues is attainable, this would significantly reduce the concerns 
of off-target toxicities that have beset other oxidovanadium complexes in chronic disease treatment models. 
Finally, since liposomal AL3 induced several-fold stronger cell differentiation and AKT activation compared 
to ethanol delivery, this liposomal approach may generate a better therapeutic index at lower oxidovanadium 
doses in vivo, again offsetting concerns with off-target toxicities. The liposomal packaging of oxidovanadium 
complexes is therefore demonstrated to be a viable approach and should be further tested now in pre-clinical 
models. Ultimately it would be envisioned for delivery as an intravenous therapeutic, in common with current 
liposomal  formulations65.
In conclusion, we have provided evidence of good bioactivity of stable, hydrophobic oxidovanadium com-
plexes in neuroblastoma cells. Moreover, in the first proof-of-concept, we can now deliver such complexes using 
liposomal nanotechnology, opening up new opportunities for demonstrating the anti-cancer potential of oxido-
vanadium complexes in pre-clinical cancer models. This would not only be of relevance to neuroblastoma, but 
also other oxidovanadium-sensitive cancers. If successful pre-clinically, this would strengthen the prospects of 
generating liposomal formulations for the safe application of oxidovanadium complexes in humans.
Materials and methods
cell culture. Neuroblastoma cell lines used were as follows: KELLY/N206 cells were kindly provided by Prof. 
Frank Speleman, University of Ghent; SK-N-SH and IMR32 cells were from ATCC. All cells were STR validated 
at source or in our laboratory. All cells were cultured in RPMI 1640 + GlutaMAX (Gibco), 10% foetal bovine 
serum (FBS) (Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin (P/S; Gibco), except for SK-N-SH, which 
were cultured in MEM (Gibco), 10% FBS, 1% P/S, 2 mM l-glutamine (Invitrogen, California, USA). Cells were 
maintained at 37 °C in 5%  CO2 and high humidity.
chemicals. All chemicals were purchased from Sigma-Aldrich, UK unless otherwise stated. BMOV was 
from ORGANICA Feinchemie GmbH Wolfen, Germany. Complexes AL1–4 and their ligands were synthesised 
as described  previously37–39. The solubility of these complexes in water is negligible as measured by spectroscopic 
(UV, 51 V NMR) methods. For treatment of cells, the compounds AL1–4 were dissolved in ethanol and used at 
a final solvent concentration of 1% on cells, controlled for by using solvent-only treatments.
Monochlorobimane assay. Cells were seeded into black-walled 96-well plates (Corning Costar TC-
Treated 96-well assay plates) and treated with chemicals the following day in triplicate. At the end of the assay, 
media was removed and replaced with 100 µl of 50 µM monochlorobimane (MCB) diluted in PBS. Fluorescence 
was read immediately and after 75 min using a FLUOstar OPTIMA plate reader (BMG LabTech, UK) (absorb-
ance 360 nm; emission 460 nm).
neurite length assay. Five thousand SK-N-SH cells were seeded per well in 12-well plates and chemically 
treated the next day. After treatment, phase-contrast images were recorded (ten fields of view per well) with an 
Olympus IX71 inverted microscope and a Hamamatsu Orca R2 monochrome camera and randomised for blind 
analysis. The length of the neurites in each image was measured using the NeuroJ plugin on  ImageJ76. Only neu-
rites longer than the cell body were measured and an average neurite length per field was calculated.
cell viability assays. The remaining cells after cell viability assays were counted using nuclear labelling 
with Hoechst 33342. Half of the cell media was removed and replaced with fresh media containing 2 μg/ml 
Hoechst 33342 (Cayman Chemical, Michigan, USA; final concentration 1  μg/ml). Plates were incubated for 
at least 30 min, before fluorescence imaging. The ImageJ ‘find maxima’ tool was used with a tolerance of 2 to 
count nuclei in each image. Low-power images were taken in the centre of each well and the average nuclear 
count calculated across the triplicate wells. For crystal violet assays, cells were seeded in triplicates and at the 
end point of experiments the media was removed and cells were fixed in 4% paraformaldehyde (PFA) at room 
temperature for 10 min. Cells were stained with crystal violet (1% crystal violet; 15% methanol) for 1 h at room 
temperature, washed in distilled water, and air dried overnight. Crystal violet stain was solubilised in 20% acetic 
acid (v/v) by shaking at room temperature for several hours, and absorbance at 595 nm was measured using a 
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FLUOstar OPTIMA plate reader (BMG LabTech, UK). Resazurin (Sigma-Aldrich) was used according to the 
manufacturer’s protocol.
immunoblotting. Proteins in cell lysates were prepared in 50 mM Tris-base, pH 7.6; 150 mM NaCl; 1% 
Triton X-100; 0.02% sodium azide. 1  mM protease inhibitor cocktail (Roche, Switzerland) was added along 
with 1 mM sodium orthovanadate and 25 mM sodium fluoride. Protein concentrations were calculated using 
the Bradford reagent (Bio-Rad, California, USA) as per manufacturer’s instructions. Lysates were mixed with 
4 × sample loading buffer (25 mM Tris–HCl, pH 6.8; 60% glycerol (v/v); 8% SDS (w/v); 10% (v/v) β mercaptoe-
thanol), heated to 100 °C for 5 min, then separated using sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis in a Mini-PROTEAN Tetra assembly (Bio-Rad). Precision Plus Protein Standards (Bio-Rad) were used. 
After transfer to polyvinyldifluoride (Immobilon—Merck Millipore, Massachusetts, USA) using a wet transfer 
in a Bio-Rad Mini Trans-Blot tank, membranes were blocked for 1 h in 10% (w/v) non-fat milk powder (Mar-
vel) dissolved in 50 mM Tris-base, pH 7.4, 150 mM NaCl, 0.1% (v/v) Tween-20 (TBST). Primary antibodies 
were diluted in blocking buffer with 0.05% (w/v) sodium azide and membranes were incubated overnight at 
4 °C followed by washing and incubation for 1 hr with Horseradish peroxidase (HRP)-conjugated secondary 
antibodies. After washing, HRP was detected using Pierce ECL Plus western blotting substrate (Thermo Fisher 
Scientific, Massachusetts, USA) and X-ray film (Amersham Hyperfilm, GE Healthcare). Filters were stripped 
for re-probing using 0.2 M NaOH (20 min at 37 °C followed by 20 min at room temperature). X-ray film bands 
were quantified using ImageJ. All antibodies were purchased from Cell Signaling Technologies, UK: GAPDH 
(CST2118), phospo-AKT (CST4060), AKT (CST9272), phosphor-ERK (CST9106), ERK (CST9102).
Liposomes. Liposomes were synthesised using the thin film hydration method. Compound AL3 was dis-
solved in a molar ratio of 50:50 methanol:chloroform solution at 5 µg/ml, and stock solutions of lipids DOTMA, 
DOPC (both from Avanti polar lipids, Alabaster, AL, USA) and cholesterol (Sigma-Aldrich, Dorset, UK) were 
each prepared at 10 mg/ml in chloroform. DOTMA, DOPC, cholesterol and AL3 were mixed in a round-bot-
tomed flask to a final volume of 500 µl at a molar ratio of 35:35:20:10 (37.5:37.5:25 for empty liposomes). Rotary 
evaporation (vacuum pump V-700, Rotavapor R-3—Buchi, Flawil, Switzerland) at room temperature for 30 min 
was followed by rehydration in 1  ml nuclease free water and rotating overnight, followed by sonication for 
30–40  min (XB3 Ultrasonic Bath). Size/charge analysis was performed using the Zetasizer Nano ZS system 
(Malvern Panalytical, UK). The liposomal concentration was 1 mg/ml, giving a final concentration of 0.54 mM 
for DOTMA and DOPC, 0.31 mM cholesterol and 0.15 mM AL3.
Liposome dialysis. Five hundred microlitres of liposomes were dialysed within 48 h of liposome synthesis 
using Slide-A-Lyzer MINI dialysis devices with a molecular weight cut-off of 10 KDa (Thermo Fisher Scientific, 
Massachusetts, USA). Dialysis was against 13 ml distilled water at 4 °C, shaking for 24 h. The dialysis buffer was 
replaced twice with fresh sterile water after 4 and 18 h.
High performance liquid chromatography (HPLC). Reverse-phase HPLC was used to measure the 
concentration of compound AL3 within liposomal formulations. 50 µl samples were separated using the JASCO 
Automated HPLC System. A Hypersil MOS-2 (C8) reverse-phase HPLC column (Thermo Fisher Scientific, 
Massachusetts, USA—30,305–254,630) was used with 5 µm particle size, 250 mm column length and 4.6 mm 
internal column diameter. Mobile phase A was water and mobile phase B was 100% acetonitrile. The optimal 
absorption measurement for AL3 was found to be 360 nm and from this a standard curve was generated using 
ethanol-solubilised AL3. Data was collected using the EZChrom Elite V 3.17 software.
Statistics. Data were analysed using analysis of variance (ANOVA). For ANOVA, post hoc testing was per-
formed using the Dunnett test when all experimental conditions were compared to the same control, or Bonfer-
roni when multiple comparisons were needed. Statistical tests were performed using SPSS (IBM SPSS Statistics 
25) and significant changes (*p < 0.05, **p < 0.01, ***p < 0.001) are indicated throughout.
Received: 12 March 2020; Accepted: 15 September 2020
References
 1. Barrio, D. A. & Etcheverry, S. B. Potential use of vanadium compounds in therapeutics. Curr. Med. Chem. 17, 3632–3642 (2010).
 2. Evangelou, A. M. Vanadium in cancer treatment. Crit. Rev. Oncol. Hematol. 42, 249–265 (2002).
 3. Rehder, D. The potentiality of vanadium in medicinal applications. Future Med. Chem. 4, 1823–1837 (2012).
 4. Thompson, K. H. et al. Vanadium treatment of type 2 diabetes: A view to the future. J. Inorg. Biochem. 103, 554–558 (2009).
 5. Crans, D. C., Henry, L., Cardiff, G. & Posner, B. I. Developing vanadium as an antidiabetic or anticancer drug: A clinical and 
historical perspective. Metal Ions Life Sci. 19, 203–230 (2019).
 6. Domingo, J. L. Vanadium and tungsten derivatives as antidiabetic agents: A review of their toxic effects. Biol. Trace Elem. Res. 88, 
97–112 (2002).
 7. Bishayee, A., Waghray, A., Patel, M. A. & Chatterjee, M. Vanadium in the detection, prevention and treatment of cancer: the in vivo 
evidence. Cancer Lett 294, 1–12 (2010).
 8. Domingo, J. L. & Gómez, M. Vanadium compounds for the treatment of human diabetes mellitus: A scientific curiosity? A review 
of thirty years of research. Food Chem. Toxicol. 95, 137–141 (2016).
14
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:16660  | https://doi.org/10.1038/s41598-020-73539-6
www.nature.com/scientificreports/
 9. Scior, T., Guevara-Garcia, J. A., Do, Q.-T., Bernard, P. & Laufer, S. Why antidiabetic vanadium complexes are not in the pipeline 
of “big pharma” drug research? A critical review. Curr. Med. Chem. 23, 2874–2891 (2016).
 10. Roy, S., Banerjee, S. & Chakraborty, T. Vanadium quercetin complex attenuates mammary cancer by regulating the P53, Akt/
mTOR pathway and downregulates cellular proliferation correlated with increased apoptotic events. Biometals : an international 
journal on the role of metal ions in biology, biochemistry, and medicine 31, 647–671 (2018).
 11. Pisano, M. et al. Antiproliferative activity of vanadium compounds: Effects on the major malignant melanoma molecular pathways. 
Metallomics Integr. Biomet. Sci. 11, 1687–1699 (2019).
 12. Griffin, E., Levina, A. & Lay, P. A. Vanadium(V) tris-3,5-di-tert-butylcatecholato complex: Links between speciation and anti-
proliferative activity in human pancreatic cancer cells. J. Inorg. Biochem. 201, 110815–110815 (2019).
 13. Nechay, B. R. Mechanisms of action of vanadium. Annu. Rev. Pharmacol. Toxicol. 24, 501–524 (1984).
 14. Heneberg, P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr. Med. Chem. 16, 706–733 
(2009).
 15. Brandão, T. A. S., Hengge, A. C. & Johnson, S. J. Insights into the reaction of protein-tyrosine phosphatase 1B: Crystal structures 
for transition state analogs of both catalytic steps. J. Biol. Chem. 285, 15874–15883 (2010).
 16. Julien, S. G., Dube, N., Hardy, S. & Tremblay, M. L. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 11, 35–49 
(2011).
 17. Neel, B. G. & Tonks, N. K. Protein Tyrosine Phosphatases in Cancer (Springer, New York, 2016).
 18. Elson, A. Stepping out of the shadows: Oncogenic and tumor-promoting protein tyrosine phosphatases. Int. J. Biochem. Cell Biol. 
96, 135–147 (2018).
 19. Edel, A. L. et al. Short-term bioaccumulation of vanadium when ingested with a tea decoction in streptozotocin-induced diabetic 
rats. Metab. Clin. Exp. 55, 263–270 (2006).
 20. Zhang, S.-Q., Zhong, X.-Y., Chen, G.-H., Lu, W.-L. & Zhang, Q. The anti-diabetic effects and pharmacokinetic profiles of 
bis(maltolato)oxovanadium in non-diabetic and diabetic rats. J. Pharm. Pharmacol. 60, 99–105 (2008).
 21. Setyawati, I. A. et al. Kinetic analysis and comparison of uptake, distribution, and excretion of 48V-labeled compounds in rats. J. 
Appl. Physiol. 1985(84), 569–575 (1998).
 22. Le, M., Rathje, O., Levina, A. & Lay, P. A. High cytotoxicity of vanadium(IV) complexes with 1,10-phenanthroline and related 
ligands is due to decomposition in cell culture medium. J. Biol. Inorg. Chem. 22, 663–672 (2017).
 23. Levina, A. & Lay, P. A. Stabilities and biological activities of vanadium drugs: What is the nature of the active species?. Chem. Asian 
J. 12, 1692–1699 (2017).
 24. Levina, A. et al. Reactivity-activity relationships of oral anti-diabetic vanadium complexes in gastrointestinal media: an X-ray 
absorption spectroscopic study. Metallomics 6, 1880–1888 (2014).
 25. Scior, T., Mack, H.-G., García, J. A. G. & Koch, W. Antidiabetic Bis-Maltolato-OxoVanadium(IV): Conversion of inactive trans- to 
bioactive cis-BMOV for possible binding to target PTP-1B. DDDT 2, 221–231 (2009).
 26. Song, B., Aebischer, N. & Orvig, C. Reduction of [VO2(ma)2]- and [VO2(ema)2]- by ascorbic acid and glutathione: Kinetic studies 
of pro-drugs for the enhancement of insulin action. Inorg. Chem. 41, 1357–1364 (2002).
 27. Kiss, T., Kiss, E., Garribba, E. & Sakurai, H. Speciation of insulin-mimetic VO(IV)-containing drugs in blood serum. J. Inorg. 
Biochem. 80, 65–73 (2000).
 28. Pessoa, J. C. & Tomaz, I. Transport of therapeutic vanadium and ruthenium complexes by blood plasma components. Curr. Med. 
Chem. 17, 3701–3738 (2010).
 29. Reytman, L., Braitbard, O., Hochman, J. & Tshuva, E. Y. Highly effective and hydrolytically stable vanadium(V) amino phenolato 
antitumor agents. Inorg. Chem. 55, 610–618 (2016).
 30. Liu, Y. et al. Green synthesis of oxovanadium(IV)/chitosan nanocomposites and its ameliorative effect on hyperglycemia, insulin 
resistance, and oxidative stress. Biol. Trace Elem. Res. 169, 310–319 (2016).
 31. Lichawska, M. E., Bodek, K. H., Jezierska, J. & Kufelnicki, A. Coordinative interaction of microcrystalline chitosan with oxovana-
dium (IV) ions in aqueous solution. Chem. Cent. J. 8, 50–50 (2014).
 32. Chen, Y. et al. Degradable vanadium disulfide nanostructures with unique optical and magnetic functions for cancer theranostics. 
Angewandte Chemie (Int. Ed English) 56, 12991–12996 (2017).
 33. Rizvi, S. A. A. & Saleh, A. M. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm. J. 26, 64–70 (2018).
 34. Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H. & Car, H. Nanoparticles as drug delivery systems. Pharmacol. Rep. 64, 
1020–1037 (2012).
 35. Clark, O. et al. Oxovanadium-based inhibitors can drive redox-sensitive cytotoxicity in neuroblastoma cells and synergise strongly 
with buthionine sulfoximine. Cancer Lett. 357, 316–327 (2015).
 36. Clark, O., Daga, S. & Stoker, A. W. Tyrosine phosphatase inhibitors combined with retinoic acid can enhance differentiation of 
neuroblastoma cells and trigger ERK- and AKT-dependent, p53-independent senescence. Cancer Lett. 328, 44–54 (2013).
 37. Hanninen, M. M. et al. Vanadium complexes with multidentate amine bisphenols. Dalton Trans. 43, 14022–14028 (2014).
 38. Salonen, P., Peuronen, A. & Lehtonen, A. Oxidovanadium(V) amine bisphenolates as epoxidation, sulfoxidation and catechol 
oxidation catalysts. Inorg. Chem. Commun. 86, 165–167 (2017).
 39. Wichmann, O., Sopo, H., Lehtonen, A. & Sillanpää, R. Oxidovanadium(V) complexes with aminoethanol Bis(phenolate) [O, N, 
O, O′] ligands: Preparations, structures, N-dealkylation and condensation reactions. Eur. J. Inorg. Chem. 2011, 1283–1291 (2011).
 40. Reytman, L., Braitbard, O. & Tshuva, E. Y. Highly cytotoxic vanadium(V) complexes of salan ligands; insights on the role of 
hydrolysis. Dalton Trans. (Cambridge, England : 2003) 41, 5241–5247 (2012).
 41. Sies, H. & de Groot, H. Role of reactive oxygen species in cell toxicity. Toxicol. Lett. 64–65 Spec No, 547–551 (1992).
 42. Fernandez-Checa, J. C. & Kaplowitz, N. The use of monochlorobimane to determine hepatic GSH levels and synthesis. Anal. 
Biochem. 190, 212–219 (1990).
 43. Applebaum, M. A., Desai, A. V., Glade Bender, J. L. & Cohn, S. L. Emerging and investigational therapies for neuroblastoma. Expert 
Opin. Orphan Drugs 5, 355–368 (2017).
 44. Irving, E. & Stoker, A. W. Vanadium compounds as PTP inhibitors. Molecules 22, 2269 (2017).
 45. Kremer, L. E., McLeod, A. I., Aitken, J. B., Levina, A. & Lay, P. A. Vanadium(V) and -(IV) complexes of anionic polysaccharides: 
Controlled release pharmaceutical formulations and models of vanadium biotransformation products. J. Inorg. Biochem. 147, 
227–234 (2015).
 46. Levina, A., Crans, D. C. & Lay, P. A. Speciation of metal drugs, supplements and toxins in media and bodily fluids controls in vitro 
activities. Coord. Chem. Rev. 352, 473–498 (2017).
 47. Kiss, T., Enyedy, ÉA., Jakusch, T. & Dömötör, O. Speciation of metal complexes of medicinal interest: Relationship between solution 
equilibria and pharmaceutical properties. Curr. Med. Chem. 26, 580–606 (2019).
 48. Bilip, M. et al. Liposomal delivery of hydrophobic RAMBAs provides good bioavailability and significant enhancement of retinoic 
acid signalling in neuroblastoma tumour cells. J. Drug Target, 1–12 (2020).
 49. Yamamoto, E., Miyazaki, S., Aoyama, C. & Kato, M. A simple and rapid measurement method of encapsulation efficiency of 
doxorubicin loaded liposomes by direct injection of the liposomal suspension to liquid chromatography. Int. J. Pharm. 536, 21–28 
(2018).
 50. Carter, D. R. et al. Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. Mol. 
Oncol. 10, 866–878 (2016).
15
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16660  | https://doi.org/10.1038/s41598-020-73539-6
www.nature.com/scientificreports/
 51. Anderson, C. P. et al. Depletion of glutathione by buthionine sulfoximine is cytotoxic for human neuroblastoma cell lines via 
apoptosis. Exp. Cell Res. 246, 183–192 (1999).
 52. Kowalski, S. et al. New oxidovanadium(IV) coordination complex containing 2-methylnitrilotriacetate ligands induces cell cycle 
arrest and autophagy in human pancreatic ductal adenocarcinoma cell lines. Int. J. Mol. Sci. 20, 261 (2019).
 53. Zegke, M., Spencer, H. L. M. & Lord, R. M. Fast, facile and solvent-free dry-melt synthesis of oxovanadium(IV) complexes: Simple 
design with high potency towards cancerous cells. Chemistry (Weinheim an der Bergstrasse, Germany) 25, 12275–12280 (2019).
 54. Sálice, V. C., Cortizo, A. M., Gómez Dumm, C. L. & Etcheverry, S. B. Tyrosine phosphorylation and morphological transformation 
induced by four vanadium compounds on MC3T3E1 cells. Mol. Cell Biochem. 198, 119–128 (1999).
 55. Radha, V., Nambirajan, S. & Swarup, G. Subcellular localization of a protein-tyrosine phosphatase: Evidence for association with 
chromatin. Biochem. J. 299(Pt 1), 41–47 (1994).
 56. Zhang, J. et al. Mitochondrial phosphatase PTPMT1 is essential for cardiolipin biosynthesis. Cell Metab. 13, 690–700 (2011).
 57. Lorenzo, O., Urbe, S. & Clague, M. J. Systematic analysis of myotubularins: heteromeric interactions, subcellular localisation and 
endosome related functions. J Cell Sci 119, 2953–2959 (2006).
 58. Soares, S. S., Gutiérrez-Merino, C. & Aureliano, M. Mitochondria as a target for decavanadate toxicity in Sparus aurata heart. 
Aquat. Toxicol. 83, 1–9 (2007).
 59. Scior, T., Mack, H.-G., García, J. A. G. & Koch, W. Antidiabetic Bis-Maltolato-OxoVanadium(IV): Conversion of inactive trans- to 
bioactive cis-BMOV for possible binding to target PTP-1B. Drug Des. Dev. Ther. 2, 221–231 (2009).
 60. Tagalakis, A. D. et al. Peptide and nucleic acid-directed self-assembly of cationic nanovehicles through giant unilamellar vesicle 
modification: Targetable nanocomplexes for in vivo nucleic acid delivery. Acta Biomater. 51, 351–362 (2017).
 61. Tagalakis, A. D. et al. In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor 
in conjunctival fibrosis. J. Nanobiotechnol. 16, 97 (2018).
 62. Li, Y. et al. Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavail-
ability. AAPS J. 13, 585–597 (2011).
 63. Lee, K. D., Nir, S. & Papahadjopoulos, D. Quantitative analysis of liposome-cell interactions in vitro: Rate constants of binding 
and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 32, 889–899 (1993).
 64. Halevas, E. et al. Magnetic cationic liposomal nanocarriers for the efficient drug delivery of a curcumin-based vanadium complex 
with anticancer potential. J. Inorg. Biochem. 199, 110778–110778 (2019).
 65. Belfiore, L. et al. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and 
opportunities. J. Control. Release 277, 1–13 (2018).
 66. Pastorino, F. et al. Overcoming biological barriers in neuroblastoma therapy: The vascular targeting approach with liposomal drug 
nanocarriers. Small 15, e1804591 (2019).
 67. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic 
accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387–6392 (1986).
 68. Chernov, L. et al. Optimization of liposomal topotecan for use in treating neuroblastoma. Cancer Med. 6, 1240–1254 (2017).
 69. Grosse, S. M. et al. Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding 
and endosomally cleavable lipid and peptide linkers. FASEB J. 24, 2301–2313 (2010).
 70. Suzuki, M. & Cheung, N.-K.V. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin. Ther. Targets 19, 
349–362 (2015).
 71. Rodríguez-Nogales, C., González-Fernández, Y., Aldaz, A., Couvreur, P. & Blanco-Prieto, M. J. Nanomedicines for pediatric cancers. 
ACS Nano 12, 7482–7496 (2018).
 72. Huang, F. W. et al. PEGylated PEI-based biodegradable polymers as non-viral gene vectors. Acta Biomater. 6, 4285–4295 (2010).
 73. Tagalakis, A. D. et al. PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, 
anionic nanocomplexes. J. Control. Release 174, 177–187 (2014).
 74. Moosavian, S. A., Bianconi, V., Pirro, M. & Sahebkar, A. Challenges and pitfalls in the development of liposomal delivery systems 
for cancer therapy. Semin. Cancer Biol. (2019).
 75. Milla, P., Dosio, F. & Cattel, L. PEGylation of proteins and liposomes: A powerful and flexible strategy to improve the drug delivery. 
Curr. Drug Metab. 13, 105–119 (2012).
 76. Meijering, E. et al. Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytom. Part 
A J. Int. Soc. Anal. Cytol. 58, 167–176 (2004).
Acknowledgements
The authors wish to thank Dale Moulding for assistance with microscopy and digital imaging. This research was 
supported by the Medical Research Council UK (EI, PhD Studentship) and also by the NIHR Great Ormond 
Street Hospital Biomedical Research Centre, including support from award 17DD08 for the GOSICH core 
microscopy facility. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR 
or the Department of Health.
Author contributions
Experiments were funded and designed by E.I., A.W.S., A.D.T., S.E. and S.L.H. Experiments and/or data analysis 
were performed by E.I. R.M., A.D.T. and S.E. The manuscript was written by E.I. and A.W.S with additional 
reviewing by A.D.T., A.L. and S.L.H.
competing interests 
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https ://doi.org/10.1038/s4159 8-020-73539 -6.
Correspondence and requests for materials should be addressed to A.W.S.
Reprints and permissions information is available at www.nature.com/reprints.




Scientific RepoRtS |        (2020) 10:16660  | https://doi.org/10.1038/s41598-020-73539-6
www.nature.com/scientificreports/
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
